Kaplan-Meier Curves of Disease-Free Survival
tumors
EVENTS, TUMORS
A, For all patients, those in the epirubicin plus paclitaxel (EP) group had 89 events; those in the epirubicin and cyclophosphamide followed by paclitaxel (EC-P) group, 100 events. B, For patients with luminal A tumors, patients in the EP group had 21 events; those in the EC-P group, 19 events. C, For patients with luminal B tumors, patients in the EP group had 51 events; those in the EC-P group, 71 events. HR indicates hazard ratio.There were 77 OS events during the follow-up period, of which 39 were in the EP group and 38 were in the EC-P group. The 5-year OS for the ITT population treated with EP or EC-P was 94.7% vs 95.0%, respectively (HR, 0.95 [95% CI, 0.61-1.49]) (